Overview
ADMA market data
Price History
ADMA price chart
Valuation & Profitability
- P/E (TTM)
- 13.12 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.60 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.74 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 33.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.21 – $20.46 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.2B · P/B 9.09 · P/S 4.33.
Company News
ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M EstBenzinga · Aug 5, 2026, 8:24 PM
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M EstimateBenzinga · Aug 5, 2026, 8:14 PM
8-K filing — ADMA BIOLOGICS, INC. (ADMA)SEC EDGAR · Aug 5, 2026, 8:10 PM
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobenewswire Inc · Aug 5, 2026, 11:00 AM
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17Benzinga · Jul 15, 2026, 6:20 PM